Australia's largest stock trading and investment forum Australia's #1 stock forum

AVR

1.60%

$15.40 anteris technologies ltd

Published paper that mentions DurAVR, page-4

First 4 Last

Share
Profile

Follow
bar

675 Posts.

107

22/04/24

10:30

Post #: 73452318
Share

Originally posted by Ski123: ↑

4.2. DurAVR THV System (Anteris Technologies)DurAVR™
THV is a novel first-in-class biomimetic balloon-expandable valve made to particularly address the challenges related to the THV durability and hemodynamic performance.
DurAVR valve is made from a single piece of tissue which has been designed and molded to mimic the anatomy and performance of a native human aortic valve. This is distinct to all the other commercially available THVs that consist of three separate leaflet tissues sewn onto a valve frame.

Detailed computational fluid modeling comparing the two leaflet designs has revealed that the single-piece leaflet design facilitates optimal laminar flow which results in the uniform distribution of the leaflet stress and hence minimizes leaflet strain and prolongs durability. This results in a more uniform distribution of leaflet stress, facilitating optimal laminar flow and minimizing leaflet strain.
Furthermore, this unique leaflet design offers a larger coaptation area and improved coaptation length, reducing the risk of leaflet pin-rolling. Notably, the DurAVR THV also utilizes the novel ADAPT tissue-engineered anti-calcification technology, employing DNA- and glutaraldehyde-free acellular bovine pericardial leaflet tissue.
This decreases the risk of leaflet calcification and structural valve deterioration (SVD), contributing to the enhanced durability and longevity of the DurAVR THV System.

Additionally, the unique leaflet design allows for a shorter stent height with a spacious open cell geometry, and the ComASUR™ delivery system provides controlled deployment, potentially increasing the likelihood of achieving commissural alignment and facilitating coronary access [15].

In the first-in-human, prospective, single-arm, single-center study designed to assess the safety and feasibility of the DurAVR THV in 20 patients, procedural success was 100%, with no device-related complications.
The DurAVR demonstrated superior hemodynamics, with an effective orifice area (EOA) of 2.36 cm and a mean gradient of 7.8 mm Hg.
These hemodynamic effects were sustained at the 1-year follow-up in the first 12 patients. Furthermore, the CMR testing in the five patients matched to healthy controls showed that DurAVR maintains laminar aortic flow [15].

Expand

Interesting reading especially the comment that the aortic bicuspid valve in humans is 1 to 2 percent of the population but constitutes 50% of TAVR insertions.DurAVR seems to be the leader in valve in valve I would like data on DurAVR if used on bicuspid valve patients. 98% of the population have 3 cusps in their AV ,2% have 2 cusps. Less efficient and prone to degrading and stenosis.

AVR Price at posting: $23.00 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

IDA

Indiana Resources to win US$90M from Tanzania following international lawsuit

KGL

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

BC8

Black Cat Syndicate one pour away from being rerated as producer

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

There are more pages in this discussion • 11 more messages in this thread...

First 4 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $15.40		Change -0.250(1.60%)		Mkt cap ! $296.0M

Open	High	Low	Value	Volume
$15.75	$15.75	$15.28	$73.28K	4.744K

Buyers (Bids)

No.	Vol.	Price($)
2	219	$15.30

Sellers (Offers)

Price($)	Vol.	No.
$15.40	48	2

View Market Depth

No.	Vol.	Price($)
2	219	15.300
1	180	15.280
1	486	15.210
2	93	15.200
1	198	15.150

Price($)	Vol.	No.
15.400	48	2
15.440	308	3
15.450	75	2
15.490	20	1
15.500	77	1

Last trade - 10.44am 29/07/2024 (20 minute delay)

AVR (ASX) Chart

Published paper that mentions DurAVR, page-4

Indiana Resources to win US$90M from Tanzania following international lawsuit

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Black Cat Syndicate one pour away from being rerated as producer

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Published paper that mentions DurAVR, page-4

Top Stories

Indiana Resources to win US$90M from Tanzania following international lawsuit

KGL hits copper-silver-gold-zinc-lead massive sulphide intersection in NT

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Black Cat Syndicate one pour away from being rerated as producer

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News